The $200 million upfront payment provides significant non-dilutive funding for MeiraGTx's gene therapy programs. Traders should monitor the progress of the Phase III Parkinson's trial and the commercialization timeline for the proprietary delivery device. The recent insider selling may indicate profit-taking after the positive news.
Price Chart
Executive Summary
MeiraGTx has entered into a strategic collaboration with Hologen to co-develop and commercialize gene therapies for Parkinson's disease and genetic obesity, along with a proprietary delivery device. The deal includes a $200 million upfront payment, partially funded by a recent $100 million capital raise, and establishes a joint governance structure. Hologen will hold a 70% stake in the neuro-focused entity.
Key Financial Metrics
Key Facts
- Strategic collaboration with Hologen for gene therapy development in Parkinson's disease and genetic obesity
- Total upfront payment of $200 million, with $105 million already received
- Recent $100 million capital raise (11.1 million shares at $9.00/share) to fund the collaboration
- Hologen will own 70% of the neuro-focused entity, MeiraGTx will own 30%
- Collaboration covers AAV-GAD and AAV-BDNF investigational gene therapies and a proprietary delivery device
Financial Impact
The collaboration is funded by a $200 million upfront payment, with $105 million already received and the remainder to be funded through Hologen's purchase of MeiraGTx shares. This is supported by a recent $100 million capital raise.
Risk Factors
- Dependence on Hologen for funding the remaining $95 million of the upfront payment
- Potential delays in the Phase III Parkinson's trial
- Dilution from the recent $100 million capital raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-048196 |
| Document: mgtx-20260420xex10d1.htm | 0001104659-26-048196 |
| Document: mgtx-20260420xex10d2.htm | 0001104659-26-048196 |
| Document: mgtx-20260420x8k.htm | 0001104659-26-048196 |
| Document: 0001104659-26-048196-index-headers.html | 0001104659-26-048196 |
| Document: 0001104659-26-048196-index.html | 0001104659-26-048196 |
| Document: 0001104659-26-048196.txt | 0001104659-26-048196 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.18 (−15.16%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.18 (−15.86%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.18 (−21.87%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.18 (−38.68%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Jul 7, 2026 15w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.18 (−37.38%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.18 (−4.18%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers